Browsing Category
Pharma Industry News
4744 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Vetter breaks ground on $285m clinical site in Illinois to expand early-phase manufacturing
Vetter begins construction on a new $285M clinical manufacturing site in Illinois to boost early-phase injectable drug development. Completion slated for 2029.
Omeros seeks EMA approval for narsoplimab to treat stem cell transplant-related TA-TMA
Omeros Corporation has submitted a Marketing Authorization Application to the EMA for narsoplimab, aiming to treat TA-TMA across Europe. Learn what’s at stake.
PRD Therapeutics begins first-in-human trial for PRD001 targeting HoFH and MASH
PRD Therapeutics initiates first-in-human clinical trial of PRD001, a novel SOAT2-selective inhibitor for HoFH and MASH, showing promise in preclinical models.
Biocon Biologics gets Health Canada approval for Yesafili aflibercept biosimilar
Biocon Biologics wins Health Canada approval for Yesafili, its 10th biosimilar. Find out how this launch could reshape retinal care access in Canada.
Sona Nanotech set to launch first human trial of its gold nanoparticle cancer therapy
Sona Nanotech receives ethics approval to begin first-in-human melanoma trial using gold nanorod-based hyperthermia therapy. Patient dosing to start soon.
Hikma Pharmaceuticals commits to $1 billion U.S. generics expansion amid strategic reshoring efforts
Hikma Pharmaceuticals (LSE: HIK) will invest $1B in U.S. manufacturing and R&D to strengthen its position in the generics market and address domestic drug shortages.
Can dual agonist drugs like amycretin and tirzepatide replace bariatric surgery by 2030?
Can new obesity drugs like amycretin and tirzepatide replace bariatric surgery by 2030? Discover what clinical data and cost trends reveal about the future.
Wanbury C RED expands nationwide: Can liposomal iron therapy transform India’s anemia treatment landscape?
Wanbury rolls out C RED across India, targeting anemia with liposomal iron tech. Doctors back its tolerability. Can it disrupt the iron supplement market?
GenSight Biologics completes LUMEVOQ tech transfer to Catalent to enable global clinical expansion
GenSight Biologics advances gene therapy LUMEVOQ® through strategic manufacturing transfer to Catalent, bolstering regulatory readiness and clinical scale-up.
How does nipocalimab compare to efgartigimod and rozanolixizumab? FcRn class battlelines in gMG and beyond
Compare nipocalimab, efgartigimod, and rozanolixizumab on efficacy, safety, dosing, pricing, and market strategy in generalized myasthenia gravis treatment.